SpringWorks gains after FDA approves non-cancerous tumors treatment for adults

SpringWorks Therapeutics

28/11/2023 09:59

** Shares of SpringWorks Therapeutics  SWTX.O  up 14.9% to
about $24 in premarket trading
    ** After market close on Monday, U.S. health regulator
approved co's drug, Ogsiveo, for treating adult patients with
desmoid tumors, making it the first approved treatment for this
type of non-cancerous soft-tissue growth
    ** The monotherapy nirogacestat, branded as Ogsiveo, to be
available in the United States within 10 days of approval - CEO
    ** Desmoid tumors are rare, abnormal, non-cancerous growths
that occur in connective tissues and are associated with a high
rate of recurrence 
    ** As of last close, stock down 20.2% YTD

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))